BMPR2-E376K Mutation Identifies FOP Cases Without ACVR1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of Fibrodysplasia ossificans progressiva (FOP) is limited by the exclusive focus on ACVR1 mutations, with little known about the molecular basis of the disease and the genetic causes beyond ACVR1-R206H, which does not account for all FOP cases, particularly those without big toe anomalies or ACVR1 gene mutations.
Innovation Solution
Identification and functional validation of a gain-of-function mutation in the BMPR2 gene, specifically the BMPR2-E376K variant, which causes a FOP-like phenotype through constitutive activation of BMP signaling, leading to heterotopic ossification, and its potential use in treating bone diseases through osteogenic differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If research focuses exclusively on ACVR1 mutations, then the understanding of classic FOP cases is improved, but the understanding of FOP cases without ACVR1 mutations or with atypical features deteriorates
Solution Approach 1:
The patent expands the understanding of FOP pathogenesis by identifying BMPR2 as an additional causative gene beyond ACVR1. This multi-gene approach makes the overall understanding of FOP more universal, capable of explaining both classic ACVR1-associated cases and atypical cases without ACVR1 mutations or without big toe anomalies.
2Quantity of substance
If ACVR1-R206H mutation is identified as the primary cause, then the molecular basis for most FOP cases is explained, but the genetic causes for remaining cases remain unknown
Solution Approach 1:
The patent identifies a specific gain-of-function mutation (E376K) in the BMPR2 gene that alters the receptor's function. This parameter change in gene function expands the known genetic causes of FOP from primarily ACVR1 mutations to include BMPR2 gain-of-function mutations, thereby reducing the loss of information regarding genetic causes in atypical FOP cases.
3Ease of operation
If FOP is defined by ACVR1 mutations and big toe anomalies, then classic FOP diagnosis is simplified, but atypical FOP cases without these features are missed
Solution Approach 1:
The patent establishes BMPR2 gain-of-function mutations as another valid cause of FOP, creating a more universal diagnostic framework. This allows clinicians to diagnose FOP in atypical cases without ACVR1 mutations or without classic big toe anomalies, thereby improving diagnostic reliability while maintaining reasonable simplicity through targeted genetic testing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The BMPR2-E376K mutation is shown to induce SMAD1/5/9 phosphorylation and osteogenic differentiation markers, confirming its causative role in FOP-like phenotypes and providing insights into the molecular basis of FOP and TGF/BMP signaling, with potential therapeutic applications for bone diseases.
Implementation Method 1
The BMPR2-E376K mutation is shown to induce SMAD1/5/9 phosphorylation and osteogenic differentiation markers
Data Source
AI summary
Disclosed is a technique for identifying a mutation of a particular gene as a new case of a FOP-like phenotype, in addition to the existing ACVR1-R206H mutation known as a cause of FOP and utilizing the identified mutation in the bone disease treatment through osteogenic differentiation. There is provided a bone morphogenetic protein type 2 receptor (BMPR2)-E376K mutant in which the 376th amino acid glutamic acid (E) is mutated into lysine (K) in the BMPR2 gene encoding BMPR2.